The Journal of clinical psychiatry
-
Comparative Study Clinical Trial Controlled Clinical Trial
Treatment of major affective disorder with fluvoxamine.
A placebo-controlled, double-blind study of 63 inpatients with major affective disorder was performed to compare the safety and efficacy of fluvoxamine and imipramine. Results indicate that fluvoxamine and imipramine are superior to placebo and demonstrate a trend toward superiority of fluvoxamine over imipramine. Fluvoxamine was generally well tolerated in most patients.
-
Comparative Study Clinical Trial Controlled Clinical Trial
Implications of restrictive diagnosis for compliance to antidepressant drug therapy: alprazolam versus imipramine.
Early dropouts from a double-blind comparison of the therapeutic efficacy of alprazolam and imipramine were examined. The dropout rate across the total sample of 99 analyzable outpatients with major depression was 3 times higher in the imipramine treatment group. ⋯ Early termination in the imipramine group was concentrated in the group of depressed outpatients who failed to satisfy the Feighner criteria. Implications of these and other recently reported results for choice of drug treatment for depressed psychiatric outpatients are discussed.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study.
Forty-eight patients currently experiencing panic attacks were randomly assigned to double-blind treatment with alprazolam, diazepam, or placebo. Efficacy was assessed using the Hamilton Rating Scale for Anxiety and a panic attack frequency rating scale. Results indicate that the two active treatments appeared equally effective in reducing both the frequency of panic attacks and the severity of generalized anxiety when compared with placebo. Overall, these data support the use of benzodiazepines in the treatment of panic disorder.
-
Randomized Controlled Trial Comparative Study Clinical Trial
A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder.
The efficacy and safety of fluoxetine, a new antidepressant agent, were assessed in a double-blind, parallel, randomized study of 44 outpatients with major depressive disorder. Following a 1-week placebo period, patients were randomly assigned to either fluoxetine or amitriptyline for a period of 5 weeks. ⋯ Both drugs were effective in relieving the symptoms of depression. The most frequently reported side effects were nausea and nervousness for fluoxetine, and dry mouth, dizziness, and drowsiness for amitriptyline.
-
Carbamazepine was given to five patients with mixed frontal lobe disease and a variety of primary psychiatric disorders. All five patients benefited significantly. A decrease in affective lability was the most consistent result. Carbamazepine may be an alternative to chronic high-dose neuroleptic therapy in these patients.